@article{10902/34513,
year = {2024},
url = {https://hdl.handle.net/10902/34513},
abstract = {Background and Aim: Type 2 Diabetes mellitus (T2DM), age, and obesity are risk factors for metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to assess the performance of non-invasive tests (NITs) for the diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis in high-risk subjects. Methods: Multicentre cross-sectional study that included 124 biopsy-proven MASLD in more than 50 years-old patients with overweight/obesity and T2DM. Vibration-controlled transient elastography, Fibrosis-4 index (FIB-4), Non-alcoholic fatty liver disease fibrosis score (NFS), OWLiver Panel (OWLiver DM2 + Metabolomics-Advanced Steatohepatitis Fibrosis Score -MASEF) and FibroScan-AST were performed. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and area under the receiver operating characteristic curve (AUC) were calculated. NITs were assessed individually and in sequential/parallel combinations. Results: 35 (28.2%) patients had early MASH and 66 (53.2%) had MASH with significant fibrosis (at-risk MASH). The OWLiver Panel correctly classified 86.1% as MASH, showing an accuracy, sensitivity, specificity, PPV, and NPV of 0.77, 0.86, 0.35, 0.85, and 0.36, respectively. Class III obesity, diabetes control, or gender did not impact on the performance of the OWLiver Panel (p > 0.1). NITs for at-risk MASH showed an AUC > 0.70 except for NFS. MASEF showed the highest accuracy and NPV for at-risk MASH (AUC 0.77 [0.68?0.85], NPV 72%) and advanced fibrosis (AUC 0.80 [0.71-0.88], NPV 92%). Combinations of NITs for the identification of at-risk MASH did not provide any additional benefit over using MASEF alone. Conclusion: one-step screening strategy with the OWLiver Panel has high accuracy to detect MASH and at-risk MASH in high-risk subjects for MASLD.},
organization = {Funding: Instituto de Salud Carlos III, Grant/Award Numbers: FIS PI18/01304, PI22/01853; Pfizer, Grant/Award Number: MK‐ ESNASRDL‐13. Acknowledgments: we gratefully acknowledge the patients for their participation in this study. We thank Lorena Cayon, Sara Arias and Ana Álvarez for their excellent technical assistance. The work was supported in part by a brant from the Spanish Carlos III Health Institute (ISCIII) (J. Crespo [FIS PI18/01304, and PI22/01853] and Pfizer [MK‐ ESNASRDL‐13]).},
publisher = {Wiley-Blackwell},
publisher = {United European Gastroenterology Journal, 2024,12, 919-929},
title = {One-step non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis and fibrosis in high-risk population},
author = {Iruzubieta Coz, Paula and Mayo, Rebeca and Mincholé, Itziar and Martínez-Arranz, Ibon and Arias Loste, María Teresa and Ibáñez-Samaniego, Luis and Ampuero, Javier and Abad, Javier and Martín-Mateos, Rosa and Fernández-Laso, Ana Belén and Albillos, Agustín and Bañares, Rafael and Calleja, José Luis and Romero-Gómez, Manuel and Aller, Rocío and Crespo García, Javier},
}